GO:0019781 NEDD8 activating enzyme activity: Mechanism, Genes and Research

NEDD8 activating enzyme activity (GO:0019781) is a molecular function that catalyzes the initiation of the NEDD8 (RUB1) conjugation cascade, a process essential for the covalent attachment of the ubiquitin-like protein NEDD8 to target proteins. This enzymatic activity is the first and rate-limiting step in protein neddylation, a post-translational modification that regulates the stability, localization, and activity of numerous substrate proteins. The NEDD8 activating enzyme (NAE) is a heterodimer composed of NAE1 (also known as APPBP1) and UBA3, which together activate NEDD8 in an ATP-dependent manner before transferring it to a conjugating enzyme. Because neddylation controls the activity of cullin-RING ligases (CRLs), the largest family of E3 ubiquitin ligases, NEDD8 activating enzyme activity sits at the heart of protein degradation and cellular homeostasis. Dysregulation of NEDD8 activating enzyme activity has been linked to a wide range of human diseases, particularly cancer, where elevated neddylation supports tumor growth and survival. The discovery of MLN4924 (pevonedistat), a potent and selective inhibitor of NAE, demonstrated that targeting this activity can effectively kill cancer cells and has since spurred extensive clinical and preclinical research. Beyond oncology, emerging evidence implicates NEDD8 activating enzyme activity in ischemic brain injury, doxorubicin-induced cardiotoxicity, cardiac hypertrophy, and immune cell responses, underscoring its broad physiological importance. For researchers, understanding NEDD8 activating enzyme activity is critical because it provides a molecular entry point to manipulate the entire neddylation pathway. Knockout of NAE1 or UBA3 is embryonic lethal in mice, highlighting the essential nature of this activity. Conditional and inducible models, as well as CRISPR-mediated point mutations, are therefore necessary to study its tissue-specific and context-dependent roles. This article synthesizes the current knowledge on the mechanism, key genes, disease relevance, and research methods for studying GO:0019781, with a focus on how CRISPR-based models can accelerate discovery.

According to the Gene Ontology, NEDD8 activating enzyme activity (GO:0019781) is defined as the catalysis of the initiation of the NEDD8 (RUB1) conjugation cascade. In practical terms, this activity involves the ATP-dependent adenylation of NEDD8, followed by the formation of a thioester bond between the C-terminus of NEDD8 and a catalytic cysteine residue on the NAE1-UBA3 heterodimer. This is the first step in a three-enzyme cascade (E1-E2-E3) that ultimately attaches NEDD8 to lysine residues on substrate proteins. The synonym RUB1 activating enzyme activity reflects the homology with the yeast RUB1 pathway.

NEDD8 activating enzyme activity is the gatekeeper of the entire neddylation pathway, controlling the modification of cullin proteins and other substrates that regulate cell cycle, DNA damage responses, and signal transduction. Its central role in cancer biology has made it a prime therapeutic target, with MLN4924 advancing to clinical trials. Moreover, its involvement in non-cancer pathologies such as stroke, cardiotoxicity, and immune disorders highlights its broad biomedical significance.

The following genes and proteins are central to NEDD8 activating enzyme activity and its downstream effects.

NEDD8 activating enzyme activity is regulated at multiple levels. Transcriptionally, NAE1 and UBA3 expression can be induced by growth factors and stress signals. Post-translationally, NAE1 is subject to crotonylation, which modulates its activity and affects cardiac hypertrophy. The activity is also controlled by the availability of NEDD8 and ATP, and by interacting proteins such as DCN1 that enhance cullin neddylation. Additionally, the de-neddylase NEDP1 (SENP8) counteracts neddylation, maintaining a dynamic balance. Pharmacological inhibition by MLN4924 provides an external means to regulate this activity.

NEDD8 activating enzyme activity is frequently upregulated in cancers and supports the degradation of tumor suppressors and cell cycle inhibitors through CRL-mediated ubiquitination. Inhibition of NAE with MLN4924 induces apoptosis, autophagy, and senescence in cancer cells and has shown efficacy in preclinical models of leukemia, lymphoma, and solid tumors. MLN4924 also potentiates the anti-myeloma activity of natural killer cells, suggesting immunomodulatory effects. Targeting NAE is therefore a promising therapeutic strategy for hematological and solid malignancies.

NEDD8 activating enzyme activity contributes to cardiac pathology. Inhibition of NAE with MLN4924 mitigates doxorubicin-induced cardiotoxicity in mice by reducing oxidative stress and apoptosis. Crotonylation of NAE1 modulates cardiac hypertrophy via Gelsolin neddylation, linking neddylation to hypertrophic signaling. These findings suggest that modulating NAE activity could be cardioprotective.

In ischemic brain injury, MLN4924 reduces infarct volume and neurological deficits in mice, indicating that NAE activity exacerbates neuronal damage. The mechanism may involve CRL-mediated degradation of pro-survival factors. This positions NAE as a potential target for stroke therapy.

NEDD8 activating enzyme activity influences T-cell and NK-cell responses. Pharmacological inhibition of NAE reinvigorates T-cell responses in lymphoid neoplasia, enhancing anti-tumor immunity. In multiple myeloma, MLN4924 potentiates NK cell cytotoxicity, suggesting that NAE inhibitors can be combined with immunotherapies.

In vitro NAE activity can be measured using recombinant NAE1-UBA3, NEDD8, ATP, and E2 (UBE2M) in a thioester formation assay, followed by gel electrophoresis under non-reducing conditions. Fluorescently labeled NEDD8 allows real-time kinetic analysis. These assays are used to screen inhibitors like MLN4924.

Mass spectrometry-based proteomics can identify neddylated proteins and map modification sites. Enrichment of NEDD8-modified peptides using anti-NEDD8 antibodies or tagged NEDD8 (e.g., His-NEDD8) followed by LC-MS/MS reveals global changes upon NAE inhibition or genetic manipulation.

Genome-wide CRISPR knockout or activation screens can identify genes that modulate sensitivity to NAE inhibitors or regulate neddylation. Such screens have uncovered synthetic lethal interactions and resistance mechanisms.

Fluorescence microscopy with GFP-tagged NEDD8 or cullins can visualize neddylation dynamics in live cells. Immunofluorescence for NEDD8 on cullins at DNA damage sites or during cell cycle progression provides spatial information.

Researchers studying NEDD8 activating enzyme activity-related genes often need to determine whether a candidate gene is causally involved in neddylation, cullin regulation, or disease phenotypes. EDITGENE provides end-to-end CRISPR solutions to generate precisely engineered cell models that answer these questions.

NEDD8 activating enzyme activity (GO:0019781) is a fundamental molecular function that governs the entire neddylation pathway, with far-reaching implications for cancer, cardiovascular disease, and neurobiology. The development of MLN4924 has validated NAE as a druggable target, and ongoing research continues to uncover new roles for this activity in health and disease. CRISPR-based models are indispensable for dissecting the precise contributions of NAE1, UBA3, and downstream effectors, and EDITGENE offers comprehensive services to support such studies.